RNA-sequencing of tumor transcriptomes on an individual patient-to-patient basis may, therefore, unravel opportunities to successfully treat otherwise refractory cancer patients with drugs that are substrates of specific ABC transporters. This evidence concerns the gene ABCG2 and neoplasm.